Patent ID: 7354713
Filing Date: 2008-04-08
Classification: G01N

Abstract:
1. A method for determining prognosis of breast cancer comprising the steps of: determining the mRNA level of estrogen-related receptor γ (ERRγ) in breast cancer cells of a breast cancer patient; and comparing the ERRγ mRNA level of the patient to a median ERRγ mRNA level of a population of at least twenty-five breast cancer patients as expressed in their breast cancer cells wherein breast cancer patients with an ERRγ mRNA level higher than the median level have good prognosis and breast cancer patients with an ERRγ mRNA level lower than the median level have poor prognosis in that breast cancer patients with an ERRγ mRNA level higher than the median level are more likely to respond to hormonal blockade therapy than breast cancer patients with an ERRγ mRNA level lower than the median level.